Harbin Pharmaceutical Group Co

Harbin Pharmaceutical Group Co (HPGC) (哈药集团) is a State-owned Sino-foreign joint venture, which combining pharmaceutical research and development (R&D), manufacturing and marketing. Its headquarterss is located in Harbin, capital of Northeast China’s Heilongjiang province. 

The total asset of the group reached 16.5 billion yuan ($ 2.49 billion) in 2015, with an the annual income of 16.14 billion yuan.

It has six main business segments, which are antibiotics, OTC and healthcare products, traditional Chinese medicines, biomedicine, animal vaccines and medicine circulations. The products are sold all over China and in more than fifty countries worldwide. The market share in top-level domestic hospitals reaches 100 percent, and while that in second-level hospitals stayskeeps above 90 percent. Market shares of cephalosporin APIs and preparations, calcium supplements, and Chinese medicines for injection consistently rank first in the country. 

The group boasts a research institute covering an area of 40,000 square meters, consisting of five research and development centers, specializing in biomedicine, chemical active pharmaceutical ingredients (API), chemicals, traditional Chinese medicine and healthcare products, as well as quality inspection and analysis, and has 134 patents.

Web: http://en.hayao.com/